10x Genomics Climbed 347% While It Swung To A Loss

If you had bought 10x Genomics on 5 November 2025 and simply sat tight, the outcome has been extraordinary. Investors who held 10x Genomics over the past year are up 346.6%, including dividends. Recent headlines around Atera shipments, new cancer collaborations and an AI analysis platform make that surge look easy in hindsight. If you were weighing a purchase back then, how much weight would you have given early product uncertainty versus funding and profitability risks?

10x Genomics is not the only name tied to this theme. Zero in on 34 healthcare AI stocks and compare how each one is priced.

The Argument You Would Have Been Weighing Up On 10x Genomics

The shares cost US$13.49 at the start of the period, and anyone looking at 10x Genomics then had to choose which story felt more realistic.

The bull case pointed to a Fair Value of US$15.08, a price implied by expectations that revenue could grow 2.2% a year and that profit margins might eventually reach 14.2%. This optimistic view relied on expanding product lines, acquisitions and broader global partnerships.

The bear view anchored on a Fair Value of US$9, based on an assumption that revenue might only grow 0.9% and that funding cuts and pricing pressure could constrain progress. That more cautious stance emphasized risks from weaker U.S. research budgets, regulatory uncertainty and tougher competition.

What The Evidence Did To The 10x Genomics Argument

The launch and strong early demand for the Atera spatial biology platform supported the optimistic 10x Genomics story that new products and collaborations could deepen adoption. Earnings told a different story. Revenue fell from US$172.9 million in Q2 2025 to US$151.0 million in Q2 2026 and net margin moved from a 20.0% profit to an 11.9% loss, so the profitability leg of the bull case stayed unproven. Overall, the evidence cut both ways.

The lesson is simple. When a thesis leans on future margin recovery, track net income and net margin alongside product news. Exciting launches matter less if reported profitability drifts away from the path that was assumed in the original fair value story.

What 10x Genomics' Run Already Prices In

Today 10x Genomics trades at US$58.06 after a 346.6% gain over the past year. The selected Narrative’s Fair Value sits below this level, which signals a view that the current quote already assumes a lot going right.

The Narrative leans on AI linked demand, spatial biology enthusiasm and oncology projects, and asks whether consumables usage can offset softer instrument appetite. For today’s price to hold up, a buyer would need confidence that Atera and related workflows keep scaling fast enough to counter funding constraints and slower lab equipment orders.

"The numbers imply that the share price already embeds strong confidence in Atera driven spatial growth, AI linked demand for complex experiments, and progress toward clinical applications, which leaves limited room for disappointment if any of these drivers underperform."

The price and this Narrative do not agree. → Uncover what this Narrative says 10x Genomics is actually worth

Another Health Question To Ask

10x Genomics points you toward complex disease biology. Your next step could be therapies built on what those experiments reveal.

Across ageing and obesity, doctors want treatments that shift long term outcomes, not just numbers on a chart.

One large drug maker is trying to meet that with powerful hormone based medicines, plus cancer and brain therapies from the same playbook.

Its work on new weight loss combinations, diabetes care and targeted oncology overlaps the patient pool your 10x Genomics thesis already touches.

As those needs broaden, the business shaping next generation treatments might warrant closer attention.

That argument has a Narrative and a number behind it. → See the company one Narrative values 21% above its price

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com